摘要
Abstract
Objective To investigate the efficacy and safety of S-1 maintenance chemotherapy after first-line SOX regimen (S-1 + oxaliplatin) in advanced gastric cancer (AGC) patients.Methods Sixty-seven AGC patients who showed no disease progression after 6 cycles of first-line SOX regimen chemotherapy were enrolled.According to patients' decision,29 cases participated in the control group (optimal supportive care) and 38 cases participated in the maintenance group (S-1 40-60 mg,twice daily for 21 d;35 d a cycle).For both groups,the short-term efficacy was assessed by RECIST 1.1 for every 2 cycles,and chemotherapy toxicity was evaluated by NCI-CTCAE 4.0.If there was no obvious deterioration of clinical symptoms,the patients in the control group was evaluated every 2 months,and their survival status were determined by phone interview.Results The median time to progression (TTP) was 8.2 months for the control group and 9.8 months for the maintenance group (P =0.026).The median overall survival time (OS) was 14.6 months and l7.4 months for the two groups respectively (P =0.019).The most frequent treatment-related adverse events were grade Ⅰ-Ⅱ neutropenia,anemia,chromatosis,nausea,anorexia and fatigue in the maintenance group.No death occurred in relation to the chemotherapy.Conclusions S-1 maintenance chemotherapy improves the overall survival time of AGC patients after 6-month firstline SOX regimen treatment.Patients who showed high tolerance to first-line chemotherapy are more likely to benefit from the maintenance therapy.关键词
胃肿瘤/药物疗法/有机铂化合物/治疗应用/抗肿瘤联合化疗方案/治疗应用/氟尿嘧啶/治疗应用/氟尿嘧啶/类似物和衍生物/治疗结果Key words
stomach neoplasms/drug therapy/organoplatinum compounds/therapeutic use/antineoplastic combined chemotherapy protocols/therapeutic use/fluorouracil/therapeutic use/fluorouracil/analogs & derivatives/treatment outcome分类
医药卫生
